Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9101907 | 1.00 | CCR2 (1.00) | CCR2 | |
| SCHEMBL9101899 | 1.00 | CCR2 (1.00) | CCR2 | |
| SCHEMBL9101913 | 1.00 | CCR2 (1.00) | CCR2 | |
| SCHEMBL10066673 | 0.95 | CCR2 (0.91) | CCR2 | |
| SCHEMBL9106994 | 0.93 | CCR2 (1.00) | CCR2 | |
| SCHEMBL9106986 | 0.93 | CCR2 (1.00) | CCR2 | |
| SCHEMBL9106998 | 0.93 | CCR2 (1.00) | CCR2 | |
| SCHEMBL9106984 | 0.93 | CCR2 (1.00) | CCR2 | |
| SCHEMBL10066741 | 0.91 | CCR2 (1.00) | CCR2 | |
| SCHEMBL9108020 | 0.91 | CCR2 (1.00) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921559-B2 | 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-30 | — | — | US | disclosed |
| EP-2646429-B1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2646429-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012075115-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142733-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142733-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | CCR2, CCR5, CCR1 | CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.